Vanderbilt University Medical Center (VUMC) is committed to excellence in patient care, leadership in research, and preeminence in medical education. Our culture thrives on challenges and champions innovation, while striving to make healthcare personal.
Trofinetide as an Option for Rett Syndrome TreatmentSeptember 19th 2022
Study investigator Jeffrey L. Neul, MD, PhD, offered his perspective on the current understanding of trofinetide (Acadia Pharmaceuticals) and its potential in Rett syndrome if approved by the FDA in the coming months.
FDA Accepts Application for Trofinetide in Rett SyndromeSeptember 12th 2022
The treatment, previously known as NNZ-2566, is supported by data from the LAVENDER study. With no plans to hold an advisory meeting, the agency set a PDUFA date of March 12, 2023, for the Acadia Pharmaceuticals product.
Alzheimer Disease Risk Improved Through Major Lifestyle Factors Regardless of Socioeconomic StatusJuly 12th 2022
The risk of developing Alzheimer disease and related dementias decreased gradually with increasing scores in a dose-response manner on a model geared toward identifying healthy lifestyle factors.
Importance of National Women Physicians Day and Valuing Women in Neurology: Jan Brandes, MD, MSFebruary 3rd 2022
The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]
The Clinical Community Reaction to Roche’s Tominersen Turnaround in HuntingtonJanuary 30th 2022
After discontinuing dosing in the phase 3 GENERATION HD1 study in 2021, Roche is designing a new phase 2 trial for tominersen, its investigational antisense oligomer for Huntington disease.